A state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system

• Published in: Journal of drug delivery science and technology Vol. 86; p. 104623
• Main Authors: Assefi, Marjan, Ataeinaeini, Mehrnaz, Nazari, Ahmad, Gholipour, Arsalan, Vertiz-Osores, Jacinto Joaquin, Melody Calla-Vásquez, Kriss, Zuhair Talib Al-Naqeeb, Bashar, Hussein Jassim, Kadhim, Kalajahi, Hesam Ghafouri, Yasamineh, Saman, Dadashpour, Mehdi
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01-09-2023
• Subjects: Adjuvant; Antigen; Nanovaccine; RNA/DNA vaccines; Solid lipid nanoparticles; Antigen; Nanovaccine; Adjuvant; Solid lipid nanoparticles; RNA/DNA vaccines
• ISSN: 1773-2247
• DOI: 10.1016/j.jddst.2023.104623

In the design of vaccine generation, significant attempts have been made to produce novel vaccines and, as well, to increase the effectiveness of available vaccines versus particular diseases. Over the past few years, with nanovaccines, considerable attention has been paid to increasing vaccine effectiveness, immunization approaches, and targeted transfer to attain desirable immune reactions. Solid lipid nanoparticles (SLNs) are on the front line of the quickly advancing nanotechnology field with various powerful uses in the delivery of pharmaceutical, cosmetic active, and vaccine components, from small molecules to proteins and genes with different routes of administration. SLNs have become effective delivery techniques in vaccine generation. SLNs-based vaccines can increase site-specific transfer, antigen presentation, and triggering of innate immune reaction, strong T cell reaction, and harmlessness against infectious diseases, cancers, autoimmune diseases, and neurodegeneration. The present review will briefly explain the characteristics of SLNs and explore the other preparation methods and routes of administration, focusing on SLNs as a delivery system of the different vaccines.
[Display omitted]